Introduction:
Bioprocessing, especially in the field of cell therapies, comes with numerous challenges, including integration, analytics, data management, and automation. To address these challenges, 908 Devices and Terumo Blood and Cell Technologies (Terumo BCT) have teamed up to develop innovative solutions. This collaboration aims to add analytics and automation to Terumo’s Quantum Cell Expansion System using 908’s MAVEN, an electrochemical glucose and lactate analyzer. The goal is to continuously monitor the levels of glucose and lactate in a bioreactor during the manufacturing of cell therapies.
- Implementing Bioprocessing 4.0 requires addressing various challenges, such as integration, data analytics, and automation.
- The collaboration between 908 Devices and Terumo BCT aims to add automation and analytics to improve cell therapy manufacturing.
- The combination of 908’s MAVEN and Terumo’s Quantum Cell Expansion System enables continuous monitoring of glucose and lactate levels in bioreactors.
- Lactate levels serve as an indicator of cell viability, allowing precise timing for cell harvesting.
- The collaboration intends to expand the range of analytes that can be monitored to optimize the development and manufacturing of cell therapies.
Conclusion:
The collaboration between 908 Devices and Terumo BCT represents a significant step towards overcoming the challenges of cell therapy manufacturing. By integrating analytics and automation, the partners aim to improve the efficiency and precision of the process. Monitoring glucose and lactate levels provides valuable insights into cell behavior and viability, facilitating better decision-making in feed schedules and cell harvesting. The collaboration also highlights the importance of ongoing collaborations between industry and academia to push the boundaries of bioprocessing and optimize cell therapy development.
